【4583】Ｍ－カイオム

Execution of the Collaborative Development License and Exclusive Option Agreement for anti-Semaphorin 3A antibody developed by Chiome Bioscience
2018-03-22(15:00)

関連タグ：








March 22, 2018 Company: Chiome Bioscience Inc. Representative: Shigeru Kobayashi, President & CEO (Code: 4583, Tokyo Stock Exchange Mothers) Inquiries: Arihiko Bijohira, Executive Director & CFO Phone: +81-3-6383-3746

Execution of the Collaborative Development License and Exclusive Option Agreement for anti-Semaphorin 3A antibody developed by Chiome Bioscience

Chiome Bioscience Inc. (hereinafter, "Chiome") announced today that it has executed a Collaborative Development License and Exclusive Option Agreement (hereinafter, "Agreement") with SemaThera Inc. (Home office: Montreal, Canada; herei

関連タグ：



  Execution of the Collaborative Development License and Exclusive Option Agreement for anti-Semaphorin 3A antibody developed by Chiome Bioscience





日付 始値 高値 安値 終値 出来高
2018-03-22 341 343 338 339 72200
2018-03-20 336 342 335 341 184200
2018-03-19 347 350 338 340 247800
2018-03-16 353 355 347 347 183300
2018-03-15 352 369 345 350 502300
2018-03-14 337 354 337 350 283500
2018-03-13 334 341 333 340 110700
2018-03-12 340 342 333 336 181300

関連情報
曜日別開示状況
年月 日 月 火 水 木 金 土